文献速递心血管乳腺US

接受蒽环类化疗并左侧乳腺放疗的乳腺癌患者亚临床心脏损伤监测:一项3期试验的亚组分析

Subclinical cardiac damage monitoring in breast cancer patients treated with an anthracycline-based chemotherapy receiving left-sided breast radiation therapy: subgroup analysis from a phase 3 trial.
PubMed 文献 · Radiol Med · 2024-10-22

本研究源自3期SAFE试验,分析接受蒽环类化疗和左侧乳腺放疗的乳腺癌患者亚临床心脏损伤。39例可评估患者随机接受比索洛尔、雷米普利、两者联合或安慰剂,用标准及三维超声心动图监测。安慰剂组≥10%恶化的比例最高(36.4%),比索洛尔组11.1%、雷米普利组16.7%、联合组25%;有无亚临床损伤者的平均心脏剂量无显著差异(1.5 Gy vs 1.6 Gy,p=0.94)。

要点

  • 亚临床心脏损伤定义为整体纵向应变或三维左室射血分数较基线恶化≥10%。
  • 安慰剂组亚临床损伤比例最高(36.4%),比索洛尔组11.1%、雷米普利组16.7%、联合组25%。
  • 有无亚临床损伤者的平均心脏剂量无显著差异(1.5 Gy vs 1.6 Gy,p=0.94)。

核心结论

  • 结果强调心脏保护措施在减轻不良效应中的关键作用,提示放疗对心脏功能的影响可忽略;需要对全系列进行延长随访评估,以确定亚临床效应是否可能显著影响临床结局和心脏事件。

研究设计与样本

  • 3期SAFE试验(ClinicalTrials.gov标识符:NCT2236806)的亚组分析,纳入46例接受放疗者中的39例左侧乳腺放疗患者,随机接受心脏保护药物治疗(比索洛尔、雷米普利或两者联合)或安慰剂,在多个时间点用标准和三维超声心动图进行心脏监测。

诊断标准与关键数值

  • 亚临床心脏损伤定义为整体纵向应变或三维左室射血分数恶化≥10%;未亚临床损伤患者平均心脏剂量1.5 Gy,亚临床心脏损伤患者平均心脏剂量1.6 Gy(p=0.94)。

局限性

  • 需要对全系列进行延长随访评估,以确定亚临床效应是否可能显著影响临床结局和心脏事件。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: This study, derived from the phase 3 SAFE trial (ClinicalTrials.gov identifier: NCT2236806), explores subclinical cardiac damage in breast cancer patients receiving anthracycline-based chemotherapy and left-sided breast radiation therapy (RT).

MATERIALS AND METHODS: Eligible patients were randomized to a cardioprotective pharmacological therapy (bisoprolol, ramipril, or both) or placebo, with cardiac surveillance at multiple time-point using standard and 3-dimensional echocardiography. Dosimetric parameters were analysed, including mean heart dose (MHD) and various metrics for heart substructures, employing advanced contouring techniques and auto-contouring software.

RESULTS: In the analysis of left-sided breast RT patients, the study encompassed 39 out of 46 irradiated individuals, focusing on GLS and 3D-LVEF outcomes with ≥ 10% worsening, defined as subclinical heart damage. Distinct RT schedules were used, with placebo exhibiting the highest ≥ 10% worsening (36.4%). In terms of treatment arms, bisoprolol exhibited 11.1% worsening, while ramipril 16.7% and bisoprolol + ramipril 25%. For patients with no subclinical damage, the mean MHD was 1.5 Gy; for patients with subclinical heart damage, the mean MHD was 1.6 Gy (p = 0.94). Dosimetric parameters related to heart and heart substructures (left anterior descending artery, right and left atrium, right and left ventricle) showed no statistically significant differences between patients with and without subclinical damage.

CONCLUSION: Our results emphasize the crucial role of cardioprotective measures in mitigating adverse effects, highlighting RT as having negligible influence on cardiac performance. An extended follow-up assessment of the whole series is warranted to determine whether a subclinical effect could significantly influence clinical outcomes and cardiac events.

来源:Radiol Med,查看原文。版权归原作者所有。

引用

  1. Marrazzo L, Meattini I, Becherini C, et al. Subclinical cardiac damage monitoring in breast cancer patients treated with an anthracycline-based chemotherapy receiving left-sided breast radiation therapy: subgroup analysis from a phase 3 trial. Radiol Med. 2024. PMID: 39436588. doi:10.1007/s11547-024-01897-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。